The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for ... for rights to the programme that includes a Phase II asset trialled for ulcerative colitis (UC) and metabolic dysfunction-associated ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly has reduced the prices of certain ...